Suchergebnisse - "Dvorkin, Mikhail"

PubPharm (27)

1

Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting : final analysis of LUCY

enthalten in: Breast cancer research and treatment | 2024

von Balmaña, J. | Fasching, P. | Couch, F. | +123

2

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310) : a randomised, open-label, international phase 3 study

enthalten in: Lancet (London, England) | 2023

von Qin, S. | Chan, S. | Gu, S. | +132

CommentIn: Lancet. 2023 Sep 30;402(10408):1108-1110. - PMID 37499669

3

Quality of life with cemiplimab plus chemotherapy for first-line treatment of advanced non-small cell lung cancer : Patient-reported outcomes from phase 3 EMPOWER-Lung 3

enthalten in: Cancer | 2023

von Makharadze, T. | Quek, R. | Melkadze, T. | +16

4

Efficacy and safety of maintenance therapy with pamiparib versus placebo for advanced gastric cancer responding to first-line platinum-based chemotherapy : Phase 2 study results

enthalten in: Cancer medicine | 2023

von Ciardiello, F. | Bang, Y. | Cervantes, A. | +15

5

Tislelizumab Versus Docetaxel in Patients With Previously Treated Advanced NSCLC (RATIONALE-303) : A Phase 3, Open-Label, Randomized Controlled Trial

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2023

von Zhou, C. | Huang, D. | Fan, Y. | +19

CommentIn: J Thorac Oncol. 2023 Jan;18(1):17-20. - PMID 36543431

6

Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer : a randomized, controlled, double-blind phase 3 trial

enthalten in: Nature medicine | 2022

von Gogishvili, M. | Melkadze, T. | Makharadze, T. | +23

7

Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer : The ASTRUM-005 Randomized Clinical Trial

enthalten in: JAMA | 2022

von Cheng, Y. | Han, L. | Wu, L. | +106

CommentIn: JAMA. 2022 Sep 27;328(12):1205-1207. - PMID 36166047

8

Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2022

von Edelman, M. | Dvorkin, M. | Laktionov, K. | +20

9

Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4) : an international, open-label, randomised, phase 3 trial

enthalten in: The Lancet. Oncology | 2022

von Kristeleit, R. | Lisyanskaya, A. | Fedenko, A. | +22

CommentIn: Lancet Oncol. 2022 Apr;23(4):440-441. - PMID 35298905

10

Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab : Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC)

enthalten in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy | 2021

von Syrigos, K. | Abert, I. | Andric, Z. | +13